NASDAQ:GNMKGenMark Diagnostics Stock Price, Forecast & News

GenMark Diagnostics' stock was trading at $5.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GNMK stock has increased by 223.8% and is now trading at $17.55. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for GenMark Diagnostics.

GenMark Diagnostics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for GenMark Diagnostics.

GenMark Diagnostics, Inc (NASDAQ:GNMK) announced its quarterly earnings data on Monday, May, 4th. The medical equipment provider reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.02. The medical equipment provider earned $38.74 million during the quarter, compared to analysts' expectations of $38.70 million. GenMark Diagnostics had a negative net margin of 40.18% and a negative return on equity of 310.58%. View GenMark Diagnostics' earnings history.

GenMark Diagnostics issued an update on its second quarter 2020 After-Hours earnings guidance on Tuesday, July, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $40.1-40.1 million, compared to the consensus revenue estimate of $31.39 million.

6 Wall Street analysts have issued 1-year target prices for GenMark Diagnostics' shares. Their forecasts range from $7.00 to $20.00. On average, they expect GenMark Diagnostics' stock price to reach $15.80 in the next year. This suggests that the stock has a possible downside of 10.0%. View analysts' price targets for GenMark Diagnostics.

News articles about GNMK stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GenMark Diagnostics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about GenMark Diagnostics.

Some companies that are related to GenMark Diagnostics include Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Inovio Pharmaceuticals (INO), Irhythm Technologies (IRTC), NuVasive (NUVA), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), Inari Medical (NARI), Cantel Medical (CMD), Glaukos (GKOS), AtriCure (ATRC), Luminex (LMNX), Silk Road Medical (SILK) and Shockwave Medical (SWAV). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GenMark Diagnostics investors own include Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), Opko Health (OPK), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Arena Pharmaceuticals (ARNA), Biocept (BIOC) and Amicus Therapeutics (FOLD).

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

GenMark Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.05%). Company insiders that own GenMark Diagnostics stock include Alan Baer Maderazo, Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Michael Kagnoff, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel and Tyler Jensen. View institutional ownership trends for GenMark Diagnostics.

GNMK stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold GenMark Diagnostics company stock in the last year include Alan Baer Maderazo, Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, John Frederick Ek, Kevin C Oboyle, Michael Gleeson, Michael John Harkins, Sarah Hollis Winkler, Scott Alexander O'brien, Scott Mendel, and Tyler Jensen. View insider buying and selling activity for GenMark Diagnostics.

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GNMK stock can currently be purchased for approximately $17.55.

GenMark Diagnostics has a market capitalization of $1.09 billion and generates $88.02 million in revenue each year. The medical equipment provider earns $-47,350,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe.

The official website for GenMark Diagnostics is www.genmarkdx.com.

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]